|
1.
|
|
9 p, 325.6 KB |
Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1) : a phase III, international, randomized, placebo-controlled study
/
Van Cutsem, E. (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Yoshino, Takayuki (Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan) ;
Lenz, H. J. (Division of Medical Oncology, Norris Comprehensive Cancer Center, Los Angeles, USA) ;
Lonardi, Sara (Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto - IRCCS, Padua) ;
Falcone, Alfredo (Department of Translational Research on New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy) ;
Limón, M. L. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Saunders, M. (Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK) ;
Sobrero, A. (Department of Medical Oncology, Azienda Ospedaliera San Martino, Genoa, Italy) ;
Park, Y S. (Department of Hematology and Oncology, Samsung Medical Center, Seoul, South Korea) ;
Ferreiro, R. (Hospital Universitario Ramón y Cajal (Madrid)) ;
Hong, Y S. (Department of Oncology, Asan Medical Center, Seoul, South Korea) ;
Tomasek, J. (Masaryk Memorial Cancer Institute (Brno, República Txeca)) ;
Taniguchi, H. (Aichi Cancer Center Hospital) ;
Ciardiello, Fortunato (Oncologia Medica, Seconda Università deli Studi di Napoli, Naples, Italy) ;
Stoehr, J. (Boehringer Ingelheim, Pharma GmbH & Co. KG, Biberach, Germany) ;
Oum'Hamed, Z. (Boehringer Ingelheim France S.A.S, Reims, France) ;
Vlassak, S. (SCS Boehringer Ingelheim Comm.V, Brussels, Belgium) ;
Studeny, M. (Division of Medicine/Clinical Development Department, Boehringer Ingelheim, Vienna, Austria) ;
Argiles, G.. (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
Angiogenesis is critical to colorectal cancer (CRC) growth and metastasis. Phase I/II studies have demonstrated the efficacy of nintedanib, a triple angiokinase inhibitor, in patients with metastatic CRC. [...]
2018 -  10.1093/annonc/mdy241
Annals of oncology, Vol. 29 (july 2018) , p. 1955-1963
|
|
|
2.
|
|
16 p, 1.5 MB |
Health-related Quality of Life in the Phase III LUME-Colon 1 Study : Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses
/
Lenz, Heinz Joseph (Division of Medical Oncology. USC Norris Comprehensive Cancer Center) ;
Argilés Martínez, Guillem (Vall d'Hebron Institut d'Oncologia) ;
Yoshino, Takayuki (Department of Gastroenterology and Gastrointestinal Oncology. National Cancer Center Hospital East) ;
Lonardi, Sara (Phase 1 Trial Unit and Medical Oncology Unit 1. Istituto Oncologico Veneto IRCCS) ;
Falcone, Alfredo (Department of Oncology. University of Pisa) ;
Limón, María Luisa (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Sobrero, Alberto (Ospedale Policlinico San Martino IRCCS) ;
Hastedt, Claudia (Boehringer Ingelheim International GmbH) ;
Peil, Barbara (Boehringer Ingelheim Pharma GmbH & Co. KG) ;
Voss, Florian (Boehringer Ingelheim Pharma GmbH & Co. KG) ;
Griebsch, Ingolf (Boehringer Ingelheim International GmbH) ;
Van Cutsem, Eric (University Hospitals Leuven (Bèlgica)) ;
Universitat Autònoma de Barcelona
Based on European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) outputs from the LUME-Colon 1 study, we compared and discussed different statistical methods for evaluating health-related quality of life data in oncology clinical trials. [...]
2019 - 10.1016/j.clcc.2019.08.005
Clinical Colorectal Cancer, Vol. 18 Núm. 4 (december 2019) , p. 269-279.e5
|
|
|
3.
|
|
15 p, 594.2 KB |
A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy : results from FIRE-3 and JACCRO 05 and 06 trials
/
Sebio, A. (Institut d'Investigació Biomèdica Sant Pau) ;
Stintzing, Sebastian (Department of Hematology and Oncology, Klinikum der Universitat, University of Munich) ;
Heinemann, V. (Department of Hematology and Oncology, Klinikum der Universitat, University of Munich) ;
Sunakawa, Yu (Keck School of Medicine, University of Southern California) ;
Zhang, W. (Keck School of Medicine, University of Southern California) ;
Ichikawa, W. (Division of Medical Oncology, Showa University) ;
Tsuji, A. (Department of Clinical Oncology, Kagawa University) ;
Takahashi, T. (Division of Medical Oncology, Showa University) ;
Parek, A. (Keck School of Medicine, University of Southern California) ;
Yang, D. (Keck School of Medicine, University of Southern California) ;
Cao, S. (Keck School of Medicine, University of Southern California) ;
Ning, Y. (Keck School of Medicine, University of Southern California) ;
Stremitzer, Stefan (Keck School of Medicine, University of Southern California) ;
Matsusaka, S. (Keck School of Medicine, University of Southern California) ;
Okazaki, S. (Keck School of Medicine, University of Southern California) ;
Barzi, A. (Keck School of Medicine, University of Southern California) ;
Berger, M. (Keck School of Medicine, University of Southern California) ;
Lenz, H-J (Keck School of Medicine, University of Southern California) ;
Universitat Autònoma de Barcelona
The Hippo pathway is involved in colorectal cancer (CRC) development and progression. The Hippo regulator Rassf1a is also involved in the Ras signaling cascade. In this work, we tested single nucleotide polymorphisms within Hippo components and their association with outcome in CRC patients treated with cetuximab. [...]
2016 - 10.1038/tpj.2016.69
The pharmacogenomics journal, october 2016
|
|
|
4.
|
|
22 p, 644.2 KB |
Germline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stage II/III colon cancer
/
Sebio, Ana (Institut d'Investigació Biomèdica Sant Pau) ;
Matsusaka, Satoshi (Keck School of Medicine, University of Southern California) ;
Zhang, Wu (Keck School of Medicine, University of Southern California) ;
Yang, Dongyun (Keck School of Medicine, University of Southern California) ;
Ning, Yan (Keck School of Medicine, University of Southern California) ;
Stremitzer, Stefan (Keck School of Medicine, University of Southern California) ;
Stintzing, Sebastian (Department of Hematology and Oncology, Klinikum der Universitat, University of Munich, Munich, Germany) ;
Sunakawa, Yu (Keck School of Medicine, University of Southern California) ;
Yamauchi, Shinichi (Keck School of Medicine, University of Southern California) ;
Fujimoto, Yoshiya (Cancer Institute Hospital. Department of Gastroenterological Surgery (Tokyo)) ;
Ueno, Masashi (Cancer Institute Hospital. Department of Gastroenterological Surgery (Tokyo)) ;
Lenz, Heinz-Josef (Keck School of Medicine, University of Southern California) ;
Universitat Autònoma de Barcelona
The Hippo pathway regulates tissue growth and cell fate. In colon cancer, Hippo pathway deregulation promotes cellular quiescence and resistance to 5-Fluorouracil. In this study 14 polymorphisms in 8 genes involved in the Hippo pathway (MST1, MST2, LATS1, LATS2, YAP, TAZ, FAT4 and RASSF1A) were evaluated as recurrence predictors in 194 patients with stages II/III colon cancer treated with 5-Fu-based adjuvant chemotherapy. [...]
2015 - 10.1038/tpj.2015.64
The pharmacogenomics journal, Vol. 16 (september 2015) , p. 312-319
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
